Molecular mechanisms of Cholangiocarcinoma progression: role of the tumor microenvironment.
Cholangiocarcinoma (CCA) is an aggressive tumor whose incidence is increasing. CCA is characterized by a strong desmoplastic reaction, a strong invasiveness and a very poor prognosis. Surgical treatment is the most used, but the results are poor because most CCAs, at the time of diagnosis, already have metastases to the local lymph nodes. The lack of effective therapies reflects the uncertainties regarding the molecular mechanisms that govern tumor progression in CCA. A typical hallmark of CCA is that cancer cells are embedded into a dense stroma containing fibrogenic cells, lymphatics and a variety of innate and adaptive immune cells. The ultimate role of the reactive tumor stroma is still incompletely understood; however, recent studies suggest that the tumor microenvironment may play a key role in CCA progression and its invasiveness. CCA cells exchange autocrine/paracrine signals to other cancer cells and to the infiltrating cell types and heavily influence their microenvironment. This cross-talk is under the control of signaling mechanisms, morphogenetic transcription factors, and oncogenes and is ultimately mediated by various cytokines, chemokines, and growth factors. In addition, extracellular vesicles (EVs), exosomes and microvesicles, containing cargo mediators, such as proteins and RNAs, play a key role in cell-to-cell communication in cancer biology, and particularly in epigenetic regulation thanks to their content in miRNAs. Both cytokine- and EV-mediated communication between CCA cells and other liver cells provide a potential novel target for the treatment of CCA.
Selected Publications:
- The Tumor Microenvironment in Cholangiocarcinoma Progression.Fabris L, Sato K, Alpini G, Strazzabosco M. Hepatology. 2021 Jan; 2020 Nov 6. PMID: 32500550.
- Cholangiocarcinoma 2020: the next horizon in mechanisms and management.Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen JB, Braconi C, Calvisi DF, Perugorria MJ, Fabris L, Boulter L, Macias RIR, Gaudio E, Alvaro D, Gradilone SA, Strazzabosco M, Marzioni M, Coulouarn C, Fouassier L, Raggi C, Invernizzi P, Mertens JC, Moncsek A, Ilyas SI, Heimbach J, Koerkamp BG, Bruix J, Forner A, Bridgewater J, Valle JW, Gores GJ. Nat Rev Gastroenterol Hepatol. 2020 Sep; 2020 Jun 30. PMID: 32606456.
- Liver Matrix in Benign and Malignant Biliary Tract Disease.Fabris L, Cadamuro M, Cagnin S, Strazzabosco M, Gores GJ. Semin Liver Dis. 2020 Aug; 2020 Mar 11. PMID: 32162285.
- The tumour microenvironment and immune milieu of cholangiocarcinoma.Fabris L, Perugorria MJ, Mertens J, Björkström NK, Cramer T, Lleo A, Solinas A, Sänger H, Lukacs-Kornek V, Moncsek A, Siebenhüner A, Strazzabosco M. Liver Int. 2019 May. PMID: 30907492.
- Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma.Cadamuro M, Brivio S, Mertens J, Vismara M, Moncsek A, Milani C, Fingas C, Cristina Malerba M, Nardo G, Dall'Olmo L, Milani E, Mariotti V, Stecca T, Massani M, Spirli C, Fiorotto R, Indraccolo S, Strazzabosco M, Fabris L. J Hepatol. 2019 Apr; 2018 Dec 14. PMID: 30553841.
- Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances.Sirica AE, Gores GJ, Groopman JD, Selaru FM, Strazzabosco M, Wei Wang X, Zhu AX. Hepatology. 2019 Apr; 2019 Mar 25. PMID: 30251463.
- Animal models of cholangiocarcinoma: What they teach us about the human disease.Cadamuro M, Brivio S, Stecca T, Kaffe E, Mariotti V, Milani C, Fiorotto R, Spirli C, Strazzabosco M, Fabris L. Clin Res Hepatol Gastroenterol. 2018 Oct; 2018 May 9. PMID: 29753731.
- The deleterious interplay between tumor epithelia and stroma in cholangiocarcinoma.Cadamuro M, Stecca T, Brivio S, Mariotti V, Fiorotto R, Spirli C, Strazzabosco M, Fabris L. Biochim Biophys Acta Mol Basis Dis. 2018 Apr; 2017 Jul 27. PMID: 28757170.
- Molecular Mechanisms Driving Cholangiocarcinoma Invasiveness: An Overview.Brivio S, Cadamuro M, Fabris L, Strazzabosco M. Gene Expr. 2018 Mar 21; 2017 Oct 25. PMID: 29070148.
- Tumor reactive stroma in cholangiocarcinoma: The fuel behind cancer aggressiveness.Brivio S, Cadamuro M, Strazzabosco M, Fabris L. World J Hepatol. 2017 Mar 28. PMID: 28396716.
- Autocrine and Paracrine Mechanisms Promoting Chemoresistance in Cholangiocarcinoma.Cadamuro M, Brivio S, Spirli C, Joplin RE, Strazzabosco M, Fabris L. Int J Mol Sci. 2017 Jan 13; 2017 Jan 13. PMID: 28098760.
- Low-Dose Paclitaxel Reduces S100A4 Nuclear Import to Inhibit Invasion and Hematogenous Metastasis of Cholangiocarcinoma.Cadamuro M, Spagnuolo G, Sambado L, Indraccolo S, Nardo G, Rosato A, Brivio S, Caslini C, Stecca T, Massani M, Bassi N, Novelli E, Spirli C, Fabris L, Strazzabosco M. Cancer Res. 2016 Aug 15; 2016 Jun 21. PMID: 27328733.
- Epithelial-to-Mesenchymal Transition and Cancer Invasiveness: What Can We Learn from Cholangiocarcinoma?Brivio S, Cadamuro M, Fabris L, Strazzabosco M. J Clin Med. 2015 Dec 19; 2015 Dec 19. PMID: 26703747.
- Leukemia inhibitory factor protects cholangiocarcinoma cells from drug-induced apoptosis via a PI3K/AKT-dependent Mcl-1 activation.Morton SD, Cadamuro M, Brivio S, Vismara M, Stecca T, Massani M, Bassi N, Furlanetto A, Joplin RE, Floreani A, Fabris L, Strazzabosco M. Oncotarget. 2015 Sep 22. PMID: 26296968.
- Isolation and characterization of biliary epithelial and stromal cells from resected human cholangiocarcinoma: a novel in vitro model to study tumor-stroma interactions.Massani M, Stecca T, Fabris L, Caratozzolo E, Ruffolo C, Furlanetto A, Morton S, Cadamuro M, Strazzabosco M, Bassi N. Oncol Rep. 2013 Sep; 2013 Jun 26. PMID: 23807641.
- Platelet-derived growth factor-D and Rho GTPases regulate recruitment of cancer-associated fibroblasts in cholangiocarcinoma.Cadamuro M, Nardo G, Indraccolo S, Dall'olmo L, Sambado L, Moserle L, Franceschet I, Colledan M, Massani M, Stecca T, Bassi N, Morton S, Spirli C, Fiorotto R, Fabris L, Strazzabosco M. Hepatology. 2013 Sep; 2013 Jul 22. PMID: 23505219.
- Unveiling the role of tumor reactive stroma in cholangiocarcinoma: an opportunity for new therapeutic strategies.Cadamuro M, Morton SD, Strazzabosco M, Fabris L. Transl Gastrointest Cancer. 2013 Jul. PMID: 28989865.
- Nuclear expression of S100A4 calcium-binding protein increases cholangiocarcinoma invasiveness and metastasization.Fabris L, Cadamuro M, Moserle L, Dziura J, Cong X, Sambado L, Nardo G, Sonzogni A, Colledan M, Furlanetto A, Bassi N, Massani M, Cillo U, Mescoli C, Indraccolo S, Rugge M, Okolicsanyi L, Strazzabosco M. Hepatology. 2011 Sep 2. PMID: 21618579.
- [Management of true precocious puberty with a delayed-action Gn-RH analog].Julesz J, Iványi T, Domokos I, Janáky T, Faredin I, László F. Orv Hetil. 1986 Dec 7. PMID: 3099244.